Study Details

Back to Search Results

A study of the safety and tolerability of ASP7317 in adults who are losing their clear, sharp central vision due to geographic atrophy secondary to dry age-related macular degeneration

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03178149

Astellas Study ID

The unique identification code given by the study sponsor.

7317-CL-0003

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Age-related Vision Loss

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

50 years - N/A

Sex

Female & Male

Product

ASP7317

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jul 2018 - Aug 2024

Masking

None (Open Label)

Enrollment number

18

A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of the safety and tolerability of ASP7317 in adults who are losing their clear, sharp central vision due to geographic atrophy secondary to dry age-related macular degeneration? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

NJ Retina

New Brunswick, United States, 08901

Other
Contact Us

Retina Consultants of Southwest Florida & National Ophthalmic Research Institute

Fort Myers, United States, 33912

Other
Contact Us

University of Washington

Seattle, United States, 98104

Other
Contact Us

Tennessee Retina, PC

Nashville, United States, 37203

Recruiting
Contact Us

Mid-Atlantic Retina

Philadelphia, United States, 19107

Recruiting
Contact Us

Retina Specialty Institute

Pensacola, United States, 35203

Recruiting
Contact Us

Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office

Boston, United States, 02114

Other
Contact Us

Jules Stein Eye Institute

Los Angeles, United States, 90095

Recruiting
Contact Us

Valley Retina Institute

McAllen, United States, 78503

Recruitment Complete
Contact Us

Retinal Consultants of Arizona LTD, Retinal Research Institute

Phoenix, United States, 85053

Other
Contact Us

Emory University Eye Center

Atlanta, United States, 30322

Recruiting
Contact Us

Stanford University Byers Eye Institute

Palo Alto, United States, 94303

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo